Could a common antibiotic ease Kids' bowel disease?
NCT ID NCT07646223
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether oral vancomycin, an antibiotic, can help children aged 6-15 with inflammatory bowel disease (IBD), especially types linked to liver problems. About 140 kids will either get vancomycin plus standard care or standard care alone for up to a year. Researchers will check if it improves symptoms, gut bacteria, and overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral vancomycin
- What this could lead to
- If it works, this could point toward a new treatment option for children with certain types of inflammatory bowel disease, especially those with liver involvement.
- What could go wrong
- This is an early Phase 2 trial with only 140 children, so results may not apply to everyone. The treatment requires long-term use and may cause side effects or not work for all types of colitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC INFLAMMATORY BOWEL DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tampere University Hospital
Tampere, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tree mushroom drink calm inflammatory bowel disease?
- A simple hospital checklist could flag hidden malnutrition in kids with IBD
- Can a new pill tame ulcerative colitis Flare-Ups?
- Could a new pill tame ulcerative colitis? a First-in-Human trial aims to find out
- Can a new pill tame ulcerative colitis when others fail?
- Can a pill tame ulcerative colitis? new trial seeks answers